The Effect of the Nutraceutical "Hemofix" on the Coagulation System

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Yocheved Grossman
Idan Grossman
Information provided by (Responsible Party):
David Varon, Hadassah Medical Organization Identifier:
First received: July 25, 2012
Last updated: July 28, 2012
Last verified: July 2012
Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the coagulation system.

Condition Intervention Phase
Von Willebrand Disease
Dietary Supplement: HEMOFIX
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Phase 1 Study of the Nutraceutical "Hemofix" Safety and Effect on the Coagulation System

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • bleeding and blood test results [ Time Frame: one year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: September 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HEMOFIX
3 grams a day
Dietary Supplement: HEMOFIX
unique complex herbal mixture


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers and volunteers with a mild bleeding disorder

Exclusion Criteria:

  • people with thrombophilic and cardiovascular complications,
  • people who are treated with anti-coagulants,
  • women taking birth control pills
  • people with a history hypercoagulability
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01651468

Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel
Contact: Hadas Lemberg, PhD    00 972 2 6777572   
Principal Investigator: David Varon, Prof         
Sponsors and Collaborators
Hadassah Medical Organization
Yocheved Grossman
Idan Grossman
Principal Investigator: David Varon, Prof HMO
  More Information

Responsible Party: David Varon, Director of coagulation unit, Hadassah Medical Organization Identifier: NCT01651468     History of Changes
Other Study ID Numbers: HEMOFIX- HMO-CTIL 
Study First Received: July 25, 2012
Last Updated: July 28, 2012
Health Authority: Israel: Ministry of Health

Keywords provided by Hadassah Medical Organization:
mild bleeding disorder

Additional relevant MeSH terms:
Von Willebrand Diseases
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Blood Platelet Disorders
Coagulation Protein Disorders
Genetic Diseases, Inborn
Genital Diseases, Female
Hematologic Diseases
Hemorrhagic Disorders
Menstruation Disturbances
Pathologic Processes
Uterine Diseases
Uterine Hemorrhage processed this record on May 26, 2016